Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Despina Fotiou and Meletios A. Dimopoulos

Abstract: The current therapeutic approach in Waldenström’s macroglobulinemia (WM) is being driven by insights in disease biology and genomic landscape. Bruton’s tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone. BTK inhibition has changed the treatment landscape of the disease. Ibrutinib has resulted in deep and durable responses both as an upfront and salvage treatment with a manageable toxicity profile. However, the need for fewer off-target effects and deeper responses has resulted in the clinical development of second-generation BTK inhibitors. Zanubrutinib has resulted in clinically meaningful antitumor activity, including deep and durable responses, with a low discontinuation rate due to treatment-related toxicities. Cardiovascular adverse events seem to be milder compared with ibrutinib. Interestingly, the efficacy of zanubrutinib in WM is significant both for MYD88L265P and MYD88WT patients. Although the randomized, phase III ASPEN clinical trial did not meet its primary endpoint in terms of showing a superiority of zanubrutinib in deep responses compared with ibrutinib, secondary efficacy and safety endpoints underscore the potential clinical role of zanubrutinib in the treatment algorithm of WM independent of the MYD88 mutational status. Combination regimens and non-covalent BTK inhibitors are emerging as promising treatment strategies. Long-term data will determine whether next-generation BTK inhibitors are more potent and safer compared with ibrutinib, and whether they are able to overcome resistance to ibrutinib, either alone or in combination with inhibitors of other interrelated molecular pathways.

Keywords: Bruton’s tyrosine kinase, ibrutinib, MYD88, Waldenström’s macroglobulinemia, zanubrutinib

Received: 11 October 2020; revised manuscript accepted: 4 January 2021.
of the VDJ recombination genes DNTT, RAG1, and RAG2, as well as upregulation of genes involved in MYD88 and CXCR4 signaling.\textsuperscript{16,17} Patterns of aberrant methylation and unique epigenomics signatures have been also described in patients with WM.\textsuperscript{18}

The diverse clinical presentation of patients with WM is attributed to the diverse bone marrow and/or organ infiltration by clonal cells and the immunological and physiochemical properties of monoclonal IgM that are primarily present in each patient. It has to be noted that treatment will not be required at the time diagnosis in up to one third of patients. The median time of asymptomatic patients to acquire features of symptomatic disease has been estimated at 5–10 years.\textsuperscript{13,19,20} Validated scoring systems are useful in stratifying asymptomatic patients with WM based on risk of progression to symptomatic disease.\textsuperscript{12} The consensus criteria for treatment initiation should be evaluated in combination with individualized clinical judgment, taking into consideration the disease complexity.\textsuperscript{21–23}

Currently, WM remains incurable with an estimated median overall survival of 10–12 years.\textsuperscript{24} Taking into consideration the indolent course of the disease and the advanced age of patients, almost half of the patients with WM die of causes unrelated to the disease. Furthermore, estimates of median survival may not reflect the survival benefit of novel therapies that have been introduced in the therapeutic armamentarium during the recent years. Although WM is an orphan disease, there are several treatment options for both newly diagnosed and relapsed WM patients. Chemoimmunotherapy, including the anti-CD20 antibody rituximab in combination with cyclophosphamide, bendamustine, or bortezomib and dexamethasone, has been considered the standard of care for many years. These treatment regimens have high response rates, induce durable responses, and present a manageable toxicity profile.\textsuperscript{22,25} Novel treatment options are imperative due to either treatment intolerance or disease refractoriness.\textsuperscript{26,27} In this context, inhibition of Bruton’s tyrosine kinase (BTK) has come to the forefront of research efforts. Ibrutinib, a first-in-class BTK inhibitor, has been the first (and only) agent to receive USA Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval for the treatment of patients with WM. However, acquired resistance and intolerance to ibrutinib have led to the clinical development of next-generation BTK inhibitors.

**BTK inhibition in WM**

BTK was discovered in 1993\textsuperscript{28} and received its name after Ogden Bruton, a pediatrician who described Bruton’s agammaglobulinemia (X-linked agammaglobulinemia), a primary immunodeficiency syndrome which involves a mutation in BTK.\textsuperscript{29} BTK is a non-receptor tyrosine kinase, which plays a central role in B-cell signaling and is necessary for normal B-cell development in the bone marrow involved in adaptive and innate receptor-mediated signals. It has an upstream role in the molecular cascade that follows the activation of the B-cell receptor (BCR) and leads to downstream pathway activation of phosphoinositide-3-kinase (P13K)–protein kinase B (AKT) pathway, phospholipase C (PLC), protein kinase C (PKC), and nuclear factor κB (NF-κB). This signaling cascade promotes B-cell differentiation, proliferation, and survival.\textsuperscript{30–32} BTK also has a role in the signaling of G-coupled chemokine receptors (like CXCR4), cytokine receptors (CD19, CD38, CD40), tumor necrosis family receptors (TNFRs), integrins and toll-like receptors (TLRs), such as TLR/MYD88.\textsuperscript{33,34}

In WM, there is constitutive activation of BTK secondary to multiple mutations, detected by multiple methods in whole bone marrow, CD19\textsuperscript{+} selected cells, peripheral blood and cell-free deoxyribonucleic acid (DNA).\textsuperscript{35–39} The first mutation described using whole-genome sequencing of CD19\textsuperscript{+} bone marrow cells, which is found in up to 90% of WM patients, is the somatic activating mutation of myeloid differentiation factor, MYD88L265P Leu265Pro.\textsuperscript{40–42} MYD88-activating mutations promote Myddosome self-assembly and trigger TLR activation via BTK interaction and signaling of interleukin 1 (IL-1), IRAK4/IRAK1 and NF-κB.\textsuperscript{43–45} Around 5–10% patients will have other MYD88 mutations or wild-type MYD88.\textsuperscript{46} MYD88\textsuperscript{WT} often has mutations in the NF-κB pathway, which are downstream to BTK and therefore show different response patterns to BTK inhibition.\textsuperscript{47,48} In addition to BTK, MYD88 mutations transactivate another tyrosine kinase, hematopoietic cell kinase (HCK) which is also involved in pro-survival signaling.\textsuperscript{49} Interestingly, HCK is also found to be a highly relevant target molecule of ibrutinib.\textsuperscript{49}
In 20–40% of patients with WM, the somatic, subclonal, activating mutation in the CXCR4 gene (C-terminal of the C-X-C chemokine receptor type 4) is identified. It is analogous to the germline mutation observed in patients with WHIM syndrome (CXCR4WHIM). The same patient may harbor different CXCR4 mutations, and this is most likely linked to genomic instability. The mutations in the C-terminal domain of the CXCR4 receptor lead to a permanently activated state by blocking the internalization of the receptor that normally occurs after SDF-1α stimulation. CXCR4 activation promotes AKT kinase and extracellular-regulated kinase (ERK) function, which may be associated with resistance to ibrutinib therapy. CXCR4WHIM status is associated with lower responses to BTK inhibition, which has provided the rationale for the clinical development of anti-CXCR4 monoclonal antibodies, such as ulocuplumab, and small molecules, such as mavorixafor. Combining BTK and CXCR4 inhibition has resulted in disease responses independent of mutational status in preclinical studies.

Overall, patients with different MYD88 and CXCR4 mutational status have distinct clinical presentations and sensitivity to BTK inhibition. MYD88L265P/CXCR4MUT patients have higher levels of bone marrow infiltration, and serum IgM and MYD88WT/CXCR4WT have the lowest levels of IgM, bone marrow infiltration and respond less well to BTK inhibition.

**Ibrutinib**

Ibrutinib is a first-in-class, orally administered BTK inhibitor. It binds irreversibly and covalently with a cysteine residue on site 481 within the binding site of BTK. In several B-cell lymphomas ibrutinib has shown potent and sustained single-agent activity. ibrutinib, like all BTK inhibitors, activates apoptosis, inhibits DNA replication, and blocks pro-survival signaling pathways. It also exerts immunomodulatory effects on macrophages and the tumor microenvironment. It inhibits HCK and causes inactivation of downstream transcription factors including NF-κB, STAT3, and AL-1 and downregulation of cytokines and chemokines.

Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia/small lymphocytic leukemia, marginal zone, and mantle-cell lymphoma. It is indicated for the treatment of patients with relapsed/refractory WM, but also for treatment-naïve, newly diagnosed patients with WM. In Europe, ibrutinib is indicated in the first line only for patients who are considered unsuitable for chemoimmunotherapy. It should be administered continuously until disease progression or unacceptable toxicity. MYD88 and CXCR4 testing is recommended before treatment initiation. Drug interruption or dose modifications are required when potent CYP3A inhibitors or inducers are co-administered or in the case of hepatic impairment, due to the fact that ibrutinib is primarily metabolized in the liver by CYP3A.

Ibrutinib is the only FDA- and EMA-approved drug for WM, which has changed the treatment and outcome landscape for the disease.

Table 1 summarizes the most important clinical data of ibrutinib in patients with WM. Following encouraging initial preliminary results, a phase II trial demonstrated the efficacy of ibrutinib in the relapsed/refractory disease setting. The median time to first response was 4 weeks and the response rates increased with increased follow up, whereas no IgM flares were reported. The mutational status was a predictor of response. The overall response rates were higher among patients with MYD88L265P/CXCR4WT (100%) and lowest for those with MYD88WT/CXCR4WT (71%). The progression-free survival (PFS) at 47 months was inferior for MYD88L265P/CXCR4WHIM (45 months) compared with patients with MYD88L265P/CXCR4WT (not reached). In addition to the above, a sub-analysis of the phase III iNNOVATE trial confirmed the efficacy of ibrutinib in rituximab refractory patients (n = 31). The response rates were similar for MYD88L265P/CXCR4WT (100%) and lowest for those with MYD88WT/CXCR4WT, ibrutinib was associated with a lower response rate in patients with CXCR4WHIM compared with those with CXCR4WT.
**Table 1.** Clinical trials of ibrutinib in WM patients.

| Patients (n) | Design/ disease setting | Treatment | Outcomes | Comments |
|-------------|--------------------------|-----------|----------|----------|
| Advani et al.\(^{64}\) | 4 RR | Phase I prospective | PO ibrutinib | ORR: 3/4 patients MRR: not reported PFS: not reported OS: not reported | |
| Treon et al.\(^{65,66}\) | 63 RR | Phase II prospective | PO ibrutinib | At 47.1 months: ORR: 90.5% MRR: 73% PFS: 2 years 69.1% OS: 2 years 95.2% Median time to response: 4 weeks | Response and PFS lower in CXCR4\(^{WHIM}\) and MYD88\(^{WT}\). Median PFS at 47.1 months: not reached for MYD88\(^{L265P}\), 45 months for MYD88\(^{L265P}/CXCR4^{WHIM}\), and 21 months for MYD88\(^{WT}/CXCR4^{WT}\) |
| Dimopoulos et al.\(^{68}\) | 31 RR (rituximab refractory) | Phase III open label | PO ibrutinib | ORR: 90% MRR: 71% PFS: 18 months 86% OS: 18 months 97% | Response and PFS similar, in MYD88\(^{L265P}/CXCR4^{WHIM}\), but slower ORR and MRR 88% for CXCR4\(^{WT}/MYD88^{L265P}\) versus 71% for CXCR4\(^{WHIM}/MYD88^{WT}\) |
| Dimopoulos et al.\(^{70}\) | 150 (TN and RR) | Phase III double blind, randomized 1:1 | Ibrutinib + rituximab \([Ibr/R]\) versus placebo + rituximab \([Pcb/R]\) | At 30-month FU: ORR: 92% in Ibr/R arm versus 72% in Pcb/R arm MRR: 47% in Ibr/R arm versus 32% in Pcb/R arm OS: 94% in Ibr/R arm versus 92% in Pcb/R arm 30-month PFS: 82% in Ibr/R versus 25% in Pcb/R Median PFS: not reached in Ibr/R versus 20.3 months in Pcb/R | PFS and RR not affected by MYD88/CXCR4 mutation status but major response lower in CXCR4\(^{WHIM}\) |
| Treon et al.\(^{69}\) | 30 TN MYD88\(^{L265P}\) | Phase II prospective | PO ibrutinib | ORR: 100% MRR: 83% PFS: 18 months 92% OS: 18 months 100% | Median time to response 4 weeks MRR was 94% in WT CXCR4 MRR was 71% in CXCR4 mutated |

MRR, major response rate; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PO, per os (orally); RR, relapsed/refractory; TN, treatment naïve; WM, Waldenström’s macroglobulinemia; WT, wild type.

previously treated patients were rituximab sensitive, whereas 45% had not received any prior treatment. Among the patients receiving ibrutinib–rituximab, ibrutinib prevented the rituximab-induced IgM flare, whereas IgM levels showed a rapid reduction, and hemoglobin level increases were sustainable.\(^{70}\) The addition of ibrutinib to rituximab resulted in a significant PFS benefit both in treatment-naïve and relapsed/refractory patients with WM, independently of the MYD88/CXCR4 mutational status. However, major response rates were lower in patients with CXCR4\(^{WHIM}\). No novel
Toxicities emerged, whereas the treatment discontinuation rate due to toxicity was similar between the two treatment groups. Furthermore, there are still unanswered questions regarding the role of ibrutinib in the therapeutic algorithm of WM. Despite the superiority of ibrutinib–rituximab compared with rituximab, there are no data available regarding the comparison of ibrutinib–rituximab with ibrutinib. Further studies evaluating the efficacy of ibrutinib–rituximab compared to other established regimens for WM both in the upfront and in the relapsed/refractory setting are needed.

Ibrutinib is also an effective treatment option for Bing–Neel syndrome as it crosses the blood–brain barrier into the central nervous system. A recent multicenter study enrolled 28 patients with Bing–Neel who received ibrutinib. A total of 85% of patients showed improvement or resolution of their symptoms, and 83% of them showed improvement in the associated abnormalities in the imaging studies, as well.

Ibrutinib has a favorable toxicity profile; however, it has multiple off-target effects because it is a non-selective agent and inhibits other molecules beyond BTK including epidermal growth-factor receptor (EGFR), ErbB2, proto-oncogene tyrosine-protein kinase (SRC), interleukin-2-inducible T-cell kinase (ITK), tyrosine-protein kinase (TEC), and HCK. Common adverse events are gastrointestinal disturbances, upper respiratory-tract infections, rash, fatigue, and dyspnea. Severe neutropenia and thrombocytopenia have been reported in up to 15% of the patients receiving ibrutinib in the abovementioned clinical trials, whereas less than 10% of the patients experienced severe infections, bleeding and arrhythmias, especially atrial fibrillation. The arrhythmogenic potential of ibrutinib seems to be mediated by the inhibition of the PI3K–AKT cardioprotective pathway. Systematic reviews of ibrutinib studies in patients with B-cell malignancies suggest a relative risk for atrial fibrillation and hypertension of 4.69 [95% confidence interval (CI): 2.17–7.64] and 2.82 [95% CI: 1.52–5.23], respectively, whereas cases of life-threatening arrhythmias have been also reported. Treatment discontinuation due to new onset of atrial fibrillation is not recommended, but patients should receive cardiological consultation and proper anticoagulation prophylaxis. Another pooled analysis of clinical trial data has suggested an increased relative risk of bleeding with ibrutinib (2.93, 95% CI: 1.14–7.52).

Ibrutinib may affect platelet aggregation by interfering with integrin signaling and von Willebrand signaling cascade. For this reason, perioperative interruption of ibrutinib is advised for 3–7 days. Importantly, the combination of ibrutinib with rituximab did not result in an excess of reported toxicities. However, the adverse events raise concern in the context of long-term, continuous treatment with ibrutinib.

Ibrutinib therapy may be interrupted to manage or prevent toxicities; however, 20% of the patients may develop withdrawal symptoms within 2 days, which typically resolve with treatment re-initiation. Ibrutinib interruption may induce a rebound effect and a hyperactive immune state similar to cytokine-release syndrome. IgM rebound may be also observed in up to 80% of patients with WM during the first 2 months following ibrutinib discontinuation. Re-initiation of treatment usually restores IgM levels and any related symptoms. The optimal strategy of interrupting ibrutinib and assuring persistence of disease response has to be determined in future studies.

Resistance to ibrutinib has been associated with poor prognosis. Mutations in the binding site of ibrutinib BTKCys481 have been identified in MYD88 mutated WM cells derived from patients progressing while on ibrutinib therapy. Interestingly, these mutations are mainly subclonal and demonstrate a variable clonal distribution. There has been evidence that these mutations occur de novo during treatment with ibrutinib. Sustained ERK 1/2 activation has also emerged as a principal mediator of ibrutinib resistance. The activation of ERK 1/2 pathway may also provide protection from BTK inhibition through a paracrine mechanism to BTK wild-type WM cells. In this context, ERK1/2 inhibition may overcome resistance. Furthermore, there have been reports of ibrutinib-resistant WM cell lines that lack BTKCys481 mutation or CXC4WHIM-like mutations, which suggest the existence of BTK-independent survival signals. Whole-exome sequencing of ibrutinib-resistant WM cells has revealed a diverse panel of both BTK-related and BTK-independent genomic abnormalities, including chromosomal deletions affecting regulators of BTK signaling, recurring mutations in ubiquitin ligases, innate immune signaling, TLR/MYD88 pathway regulators, AKT and Bcl-2 associated pathways.
**Zanubrutinib**

The need for more selective BTK inhibitors in order to minimize the off-target effects and the associated toxicity has led to the clinical development of second-generation BTK inhibitors.98 Zanubrutinib (BGB-3111) is an oral, second-generation BTK inhibitor. It binds irreversibly to the Cys481 residue of the adenosine triphosphate (ATP)-binding pocket of the BTK active site. Importantly, it has minimal off-target activity. It has a half-maximal inhibitory concentration for inhibition of off-target kinases, such as ITK, TEC, EGFR, human epidermal growth-factor receptor 2, and Janus kinase 2, 2- to 70-fold higher than ibrutinib.99–101 Zanubrutinib is currently approved by the FDA for the treatment of relapsed/refractory mantle-cell lymphoma. The recommended dose is 160 mg twice daily.102 Table 2 summarizes the results of the most important clinical trials of zanubrutinib in the treatment of WM.

The initial phase I trial enrolled 42 patients with WM, of whom nine were treatment-naïve and 33 had relapsed/refractory disease. The overall response rate was 90%, including a 75% of major response rates, whereas 1-year PFS was 91.7%. Four patients harbored MYD88L265CXCR4WHIM and all responded to treatment. Four out of five MYD88wt patients also showed responses. Regarding the safety profile, 20% of the patients experienced grade 1/2 toxicities, 35% purpura/petechia, 31% upper respiratory-tract infections and 25% constipation. Hematological toxicities (anemia and neutropenia, each in 8% of the patients) were the two most frequent grade 3/4 adverse events. Atrial fibrillation grade 2 or less was reported in 6% of the patients.101,102 Interestingly, severe hemolysis and reaction to blood transfusions have been reported in two patients receiving zanubrutinib in combination with an anti-programmed-cell-death-1 antibody in a phase I clinical trial.108

The previous study was subsequently expanded to a phase I/II trial design and included 77 patients with WM (nine treatment-naïve and 33 previously treated).103 A total of 50 patients received zanubrutinib at 160 mg twice daily and 23 were treated at 320 mg once daily. The overall response rate was 96%, whereas the rate of very good partial response or complete remission (VGPR/CR) was 45.2% after a median follow up of 36 months for the patients with relapsed/refractory disease, and 24 months for the treatment-naïve patients. Interestingly, the depth of response increased over time with 21% of the patients achieving VGPR/CR at 6 months, 33% at 12 months, and 44% at 24 months from treatment initiation. The estimated 3-year PFS rate was 81%, and the overall survival (OS) rate was 85%. The toxicity profile was considered acceptable and included contusion in 32.5% of the patients, neutropenia in 18%, major hemorrhage in 4%, atrial fibrillation in 5.2%, and diarrhea in 3%.103

Recently, the results of the phase III ASPEN clinical trial comparing zanubrutinib with ibrutinib monotherapy were reported.109,104 The study included 201 previously treated and non-eligible for chemoimmunotherapy treatment-naïve patients with WM, who were randomized to receive one of the two BTK inhibitors. All patients harbored the MYD88L265P mutation. The rate of deep responses (VGPR/CR) was 28% (n = 29) in the zanubrutinib compared with 19% (n = 19) in the ibrutinib patient group (p = 0.09). Therefore, the primary endpoint of statistical superiority in relation to deep responses (VGPR or better) was unmet. Furthermore, the major response rate among patients receiving zanubrutinib was 78% and 80% among those receiving ibrutinib, whereas the overall response rates were over 90% in both treatment groups. The 18-month PFS rate was 85% and 84%, respectively, and the 12-month OS rate was 97% and 94%, respectively. Overall, 58.4% patients experienced grade 3 or higher toxicities with zanubrutinib compared with 63.3% with ibrutinib. Patients with WM receiving zanubrutinib had a lower incidence of atrial fibrillation (3% versus 18% with ibrutinib, p < 0.05), contusion, diarrhea, peripheral edema, hemorrhage, muscle spasms, and pneumonia. The adverse events leading to treatment discontinuation were also fewer among zanubrutinib recipients. Although the incidence of neutropenia was higher with zanubrutinib (32% versus 15% with ibrutinib, p < 0.05), the rates of grade 3 or higher infections were similar in both treatment groups.109,104

The ASPEN study had also a non-randomized patient group who harbored MYD88wt. All 26 WM patients included received zanubrutinib until disease progression or unacceptable toxicity. Five patients were treatment naïve and 23 had received at least one prior line of treatment. Interestingly, the overall response rate reached
81%, including a major response rate of 50%, and a very good partial response rate of 27%. The PFS rate at 12 months was 72%. The most frequently reported toxicities included diarrhea, anemia, contusion, pyrexia, and upper respiratory-tract infection. Major hemorrhage and atrial fibrillation were reported in two patients and one patient, respectively. Following a median follow-up of 17.9 months, two patients discontinued zanubrutinib due to adverse events, whereas there were no cases of disease transformation to high-grade lymphoma.105

---

**Table 2.** Clinical trials of novel BTK inhibitors in WM patients.

| Patients (n) | Design/disease setting | Treatment | Outcomes | Comments |
|--------------|------------------------|-----------|----------|----------|
| Trotman et al.102, 2020103; Tam et al.101 | 77 (24 TN; 53 RR) | Phase I/II prospective | PO zanubrutinib | ORR: 96% VGPR/CR: 45.2% 3-year PFS: 80.5% 3-year OS: 84.8% | VGPR/CR rate increased over time: 20.5% at 6 months, 32.9% at 12 months, and 43.8% at 24 months AEIs of interest: contusion (32.5%, grade 1), neutropenia (18.2%), major hemorrhage (3.9%), atrial fibrillation/flutter (5.2%), grade 3 diarrhea (2.6%) |
| Tam et al.104; Garcia-Sanz et al.105 | 201 MYD88<sup>L265P</sup> (cohort 1) 26 MYD88<sup>WT</sup> (cohort 2) | Phase III prospective, randomized (cohort 1) | PO zanubrutinib versus ibritinib (cohort 1), PO zanubrutinib (cohort 2) | Cohort 1 VGPR/CR: 28.4% versus 19.2% ORR: 78% versus 78% MRR: 77.5% versus 77.8% 18-month PFS: 85% versus 84% Cohort 2 VGPR:26.9% ORR: 80.8% MRR: 50% 12-month PFS: 72.4% | Incidence of atrial fibrillation, contusion, diarrhea, peripheral edema, hemorrhage, muscle spasms, and pneumonia, as well as adverse events leading to treatment discontinuation, were all lower among zanubrutinib recipients; incidence of neutropenia was higher with zanubrutinib, although grade 3 or higher infection rates were similar in both groups |
| Owen et al.106 | 106 (14 TN, 92 RR) | Phase II, prospective | PO acalabrutinib | ORR: 93% MRR: 78% 24-month PFS: 90% TN, 82% RR | Common AEs: headache, diarrhoea, bruising, fatigue, nausea, arthralgia Most common grade 3 (or higher) AEs: neutropenia and lower respiratory tract infections Atrial fibrillation: 5% MYD88 wild type (n=14): PR rate = 64% |
| Sekiguchi et al.107 | 27 (18 TN, 9 RR) | Phase II, prospective | PO tirabrutinib | TN: ORR, 94.4%, MRR, 88.9% RR: ORR, 100%, MRR, 88.9% Median PFS and OS not reached | 96.2% MYD88L265P mutated Most common AEs: rash (44.4%), neutropenia (25.9%), leukopenia (22.2%) Grade ≥3 AEs: neutropenia (11.1%), lymphopenia (11.1%), leukopenia (7.4%) |

AEs, adverse events; BTK, Bruton’s tyrosine kinase; CR, complete remission; MRR, major response rate; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PO, per os (orally); RR, relapsed/refractory; TN, treatment naive; VGPR, very good partial response; WM, Waldenström’s macroglobulinemia.
Acalabrutinib

Acalabrutinib (ACP-196), is another highly selective, potent covalent BTK inhibitor. Its off-target activity is minimal.\textsuperscript{110} It has received accelerated FDA approval as monotherapy for the treatment of relapsed/refractory mantle-cell lymphoma and chronic lymphocytic leukemia.\textsuperscript{111,112} Acalabrutinib monotherapy has showed high response rates of 93\% both among treatment-naïve ($n=14$) and previously treated ($n=92$) patients with WM. Regarding 50 patients with available mutational status, the overall response rate was 94\% among MYD88\textsuperscript{L265P} patients compared with 79\% among MYD88\textsuperscript{WT} patients, and no very good partial responses were observed in the wild-type patient group. Overall, the responses were similar to those reported with ibrutinib, with a possible superior benefit for the patients with MYD88\textsuperscript{WT}. Acalabrutinib showed a similar toxicity profile with ibrutinib.\textsuperscript{113,106}

Tirabrutinib

Tirabrutinib (GS-4059/ONO) is an irreversible, selective BTK inhibitor. In a phase II trial, tirabrutinib resulted in an overall response rate of 94\% and 100\% among treatment-naïve and previously treated patients with WM after a median follow up of 6.5 and 8.3 months, respectively.\textsuperscript{107} Interestingly, the median time to major response was 1.87 months. Among the whole study population, the MYD88L265P mutation was detected in 96\% of the patients. The toxicity profile was manageable, whereas the most common adverse effects included rash, neutropenia, and leukopenia.\textsuperscript{107}

Non-covalent BTK inhibitors

Next-generation BTK inhibitors do not rely on covalent binding at the C481 site of the BTK molecule and, thus, they may bypass resistant mechanisms mediated by mutations in the C481 site.\textsuperscript{114} Two non-covalent, reversible BTK inhibitors that are being currently evaluated in WM are LOXO-305 and ARQ531. Promising preclinical data on the pharmacokinetic properties of LOXO-305 have led to an ongoing phase I/II clinical trial evaluating the maximum tolerated dose in patients with B-cell malignancies including WM [ClinicalTrials.gov identifier: NCT03740529].\textsuperscript{115} ARQ-531 is another reversible inhibitor that binds to the ATP binding region within the kinase domain of BTK without interacting with the C481 region. Interestingly, ARQ-531 also inhibits downstream effector of B-cell receptor signaling cascade including MEK, ERK, MYC and members of the SRC family kinases.\textsuperscript{116,117} In preclinical models of ibrutinib-resistant chronic lymphocytic leukemia and Richter’s transformation, ARQ-531 has shown significant activity.\textsuperscript{116,118} The results of the phase I part of the ongoing phase I/II study [ClinicalTrials.gov identifier: NCT03162536] evaluating ARQ-531 in relapsed/refractory B-cell malignancies indicated an acceptable toxicity profile and promising efficacy. The most common adverse events included gastrointestinal complaints, rash, and hematological toxicity. Ten partial responses were shown in all dose escalation levels ($n=40$). A daily dose of 65 mg has been selected as the recommended dose for further evaluation in the phase II part of the study.\textsuperscript{119}

Concluding remarks

The therapeutic approach in WM is increasingly being driven by insights in disease biology and genomic landscape. BTK plays a central role in signaling pathways for the WM clone and is constitutively activated secondary to MYD88 mutations. BTK inhibition has changed the treatment landscape of the disease. Ibrutinib has resulted in deep and durable responses both as an upfront and salvage treatment with a manageable toxicity profile. However, several challenges have emerged in order to optimize the treatment strategy including the development of more selective agents with fewer off-target effects and deeper responses, therapeutic approaches to overcome or even prevent resistance, the potential for a fixed-duration treatment regimen.\textsuperscript{120} Zanubrutinib has resulted in clinically meaningful antitumor activity, including deep and durable responses, with a low discontinuation rate due to treatment-related toxicities. Cardiovascular adverse events seem to be milder compared with ibrutinib. Interestingly, the efficacy of zanubrutinib in WM is significant both for MYD88\textsuperscript{L265P} and MYD88\textsuperscript{WT} patients. Furthermore, ongoing studies with non-covalent BTK inhibitors [ClinicalTrials.gov identifiers: NCT03740529 and NCT03162536] have shown promising efficacy and a tolerable toxicity profile in B-cell malignancies, whereas they bypass resistance mediated by mutations in the C481 site of the BTK. In an effort to enhance and optimize our current treatment strategies in WM, combinatory regimens including BTK inhibitors with CXCR4 antagonists (ulocuplumab, mavorixafor)
ClinicalTrials.gov identifiers: NCT03225716 and NCT04274738, respectively), or proteasome inhibitors (bortezomib with anti-CD20 monoclonal antibody rituximab, carfilzomib, ixazomib) [ClinicalTrials.gov identifiers: NCT03620903, NCT04263480, and NCT03506373, respectively], or bcl2 antagonists (venetoclax, APG-2575) [ClinicalTrials.gov identifiers: NCT04273139 and NCT04260217, respectively], or anti-CD38 monoclonal antibodies (daratumumab) [ClinicalTrials.gov identifier: NCT03679624], or programmed cell-death ligand-1 inhibitors (pembrolizumab) [ClinicalTrials.gov identifier: NCT02332980], are being currently evaluated in ongoing clinical trials.120 Long-term data will determine whether next-generation BTK inhibitors are more potent, safer, and able to overcome resistance to ibrutinib in WM, either alone or in combination with inhibitors of other interrelated intracellular cascades.

Conflict of interest statement
MAD declares honoraria from Beigene and Janssen. INS, MG, and DF declare that there is no conflict of interest.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Meletios A. Dimopoulos https://orcid.org/0000-0001-8990-3254

References
1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia. Semin Oncol 2003; 30: 110–115.
2. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
3. Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 2012; 118: 3793–3800.
4. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom’s macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998; 82: 1078–1081.
5. Herrinton LJ and Weiss NS. Incidence of Waldenstrom’s macroglobulinemia. Blood 1993; 82: 3148–3150.
6. Gertz MA. Waldenstrom macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 2017; 92: 209–217.
7. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66: 443–459.
8. Kastritis E, Kyrtsonis MC, Morel P, et al. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica 2015; 100: e446–e449.
9. McMaster ML. Familial Waldenstrom’s macroglobulinemia. Semin Oncol 2003; 30: 146–152.
10. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom’s macroglobulinemia. Ann Oncol 2006; 17: 488–494.
11. Paiva B, Montes MC, Garcia-Sanz R, et al. Multiparameter flow cytometry for the identification of the Waldenstrom’s clone in IgM-MGUS and Waldenstrom’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia 2014; 28: 166–173.
12. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression risk stratification of asymptomatic Waldenstrom macroglobulinemia. J Clin Oncol 2019; 37: 1403–1411.
13. Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012; 119: 4462–4466.
14. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113: 4163–4170.
15. Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenstrom’s macroglobulinemia. Leukemia 2019; 33: 2654–2661.
16. Hunter ZR, Xu L, Yang G, et al. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstrom macroglobulinemia. Blood 2016; 128: 827–838.
17. Eleutherakis-Papaiovkou E, Kastritis E, Gavriatopoulou M, et al. Circulating soluble receptor activator of nuclear factor kappa B ligand and C-C motif ligand 3 correlate with survival in patients with Waldenstrom macroglobulinemia. *Clin Lymphoma Myeloma Leuk* 2018; 18: 431–437.

18. Hunter ZR and Treon SP. Epigenomics in Waldenstrom macroglobulinemia. *Blood* 2020; 136: 527–529.

19. Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. *Blood* 2009; 113: 793–796.

20. Pophali PA, Bartley A, Kapoor P, et al. Prevalence and survival of smouldering Waldenstrom macroglobulinaemia in the United States. *Br J Haematol* 2019; 184: 1014–1017.

21. Kyle RA, Treon SP, Alexanian R, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. *Blood* 2009; 113: 793–796.

22. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s macroglobulinemia. *Semin Oncol* 2003; 30: 116–120.

23. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop on Waldenstrom’s macroglobulinemia. *Lancet Haematol* 2020; 7: e827–e837.

24. Castillo JJ, Olszewski AJ, Cronin AM, et al. Survival trends in Waldenstrom macroglobulinemia: an analysis of the surveillance, epidemiology and end results database. *Blood* 2014; 123: 3999–4000.

25. Buske C and Seymour JF. Immunochemotherapy in Waldenstrom macroglobulinemia - still the backbone of treatment. *Leuk Lymphoma* 2015; 56: 2489–2490.

26. Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, et al. How I treat rituximab refractory patients with WM. *Oncotarget* 2018; 9: 36824–36825.

27. Castillo JJ, Kanan S, Meid K, et al. Rituximab intolerance in patients with Waldenstrom macroglobulinaemia. *Br J Haematol* 2016; 174: 645–648.

28. Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. *Science* 1993; 261: 358–361.

29. Ponader S and Burger JA. Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. *J Clin Oncol* 2014; 32: 1830–1839.

30. Sideras P, Muller S, Shiel H, et al. Genomic organization of mouse and human Bruton’s agammaglobulinemia tyrosine kinase (Btk) loci. *J Immunol* 1994; 153: 5607–5617.

31. Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. *Blood* 2011; 118: 4313–4320.

32. Satterthwaite AB and Witte ON. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. *Immunol Rev* 2000; 175: 120–127.

33. de Weers M, Verschuren MC, Kraakman ME, et al. The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. *Eur J Immunol* 1993; 23: 3109–3114.

34. De Gorter DJ, Beuling EA, Kersseboom R, et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. *Immunity* 2007; 26: 93–104.

35. Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. *Blood* 2013; 121: 2522–2528.

36. Abeykoon JP, Paludo J, King RL, et al. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. *Am J Hematol* 2018; 93: 187–194.

37. Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. *Leukemia* 2018; 32: 2617–2625.

38. Ntanasis-Stathopoulos I, Bagratuni T, Gavriatopoulou M, et al. Cell-free DNA analysis
for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinopathological correlations. *Am J Hematol* 2020; 95: E148–E150.

40. Treon SP, Xu L, Yang G, *et al.* MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. *N Engl J Med* 2012; 367: 826–833.

41. Shinners NP, Carlesso G, Castro I, *et al.* Bruton’s tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family. *J Immunol* 2007; 179: 3872–3880.

42. Gray P, Dunne A, Brikos C, *et al.* MyD88 adapter-like (Mal) is phosphorylated by Bruton’s tyrosine kinase during TLR2 and TLR4 signal transduction. *J Biol Chem* 2006; 281: 10489–10495.

43. Watters TM, Kenny EF and O’Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. *Immunol Cell Biol* 2007; 85: 411–419.

44. Leleu X, Eeckhoute J, Jia X, *et al.* Targeting NF-kappaB in Waldenstrom macroglobulinemia. *Blood* 2008; 111: 5068–5077.

45. Lin SC, Lo YC and Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. *Nature* 2010; 465: 885–890.

46. Leleu X, Eeckhoute J, Jia X, *et al.* Targeting NF-kappaB in Waldenstrom macroglobulinemia. *N Engl J Med* 2015; 373: 584–586.

47. Yang G, Zhou Y, Liu X, *et al.* A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. *Blood* 2013; 122: 1222–1232.

48. Chen JG, Liu X, Munshi M, *et al.* BTK(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism. *Blood* 2018; 131: 2047–2059.

49. Yang G, Buhrlage SJ, Tan L, *et al.* HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. *Blood* 2016; 127: 3237–3252.

50. Hunter ZR, Xu L, Yang G, *et al.* The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. *Blood* 2014; 123: 1637–1646.
63. De Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. *Pharmacol Res Perspect* 2015; 3: e00156.

64. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. *J Clin Oncol* 2013; 31: 88–94.

65. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. *N Engl J Med* 2015; 372: 1430–1440.

66. Treon S, Meid K, Gustine J, et al. Long-term follow-up of previously treated patients who received ibrutinib for symptomatic Waldenstrom’s macroglobulinemia: update of pivotal clinical trial. *Blood* 2017; 130: 2776.

67. Buske C, Tedeschi A, Trotman J, et al. Ibrutinib treatment in Waldenström’s macroglobulinemia: follow-up efficacy and safety from the iNNOVATE study. *Blood* 2018; 132: 149–150.

68. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. *Lancet Oncol* 2017; 18: 241–250.

69. Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. *J Clin Oncol* 2018; 36: 2755–2761.

70. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia. *N Engl J Med* 2018; 378: 2399–2410.

71. Papanota AM, Ntanasis-Stathopoulos I, Kastritis E, et al. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia. *J Blood Med* 2019; 10: 291–300.

72. Gavriatopoulou M, Ntanasis-Stathopoulos I, Moulopoulos LA, et al. Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: a case report. *Medicine* 2019; 98: e17794.

73. Castillo JJ, Ichaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. *Blood* 2019; 133: 299–305.

74. De Weerdt I, Koopmans SM, Kater AP, et al. Incidence and management of toxicity associated with ibrutinib and rituximab: a practical approach. *Haematologica* 2017; 102: 1629–1639.
macroglobulinemia. *N Engl J Med* 2018; 379: 1975–1976.

88. Castillo JJ, Gustine JN, Meid K, *et al.* Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia. *Haematologica* 2018; 103: e466–e468.

89. Niemann CU, Herman SE, Maric I, *et al.* Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib—findings from an investigator-initiated phase II study. *Clin Cancer Res* 2016; 22: 1572–1582.

90. Ping L, Ding N, Shi Y, *et al.* The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. *Oncotarget* 2017; 8: 39218–39229.

91. Ren L, Campbell A, Fang H, *et al.* Analysis of the effects of the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib on monocyte Fcγ receptor (FcγR) function. *J Biol Chem* 2016; 291: 3043–3052.

92. Gustine JN, Meid K, Dubeau T, *et al.* Ibrutinib discontinuation in Waldenstrom macroglobulinemia: etiologies, outcomes, and IgM rebound. *Am J Hematol* 2018; 93: 511–517.

93. Castillo JJ, Gustine JN, Meid K, *et al.* Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia. *Haematologica* 2018; 103: e307–e310.

94. Martin P, Maddocks K, Leonard JP, *et al.* Postibrutinib outcomes in patients with mantle cell lymphoma. *Blood* 2016; 127: 1559–1563.

95. Xu L, Tsakmaklis N, Yang G, *et al.* Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia. *Blood* 2017; 129: 2519–2525.

96. Paulus A, Akhtar S, Yousaf H, *et al.* Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. *Blood Cancer J* 2017; 7: e565.

97. Jimenez C, Chan GG, Xu L, *et al.* Genomic evolution of ibrutinib-resistant clones in Waldenstrom macroglobulinaemia. *Br J Haematol* 2020; 189: 1165–1170.

98. Wu J, Liu C, Tsui ST, *et al.* Second-generation inhibitors of Bruton tyrosine kinase. *J Hematol Oncol* 2016; 9: 80.

99. Tam CS, LeBlond V, Novotny W, *et al.* A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia. *Future Oncol* 2018; 14: 2229–2237.

100. Li N, SZ, Liu Y, *et al.* BGB-3111 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor. In: *AACR 106th annual meeting*, Philadelphia, PA, 18–22 April 2015.

101. Tam C, GA, Opat S, *et al.* The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. *Blood* 2015; 126: 832.

102. Trotman J, Opat S, Marlton P, *et al.* Bruton’s Tyrosine Kinase (BTK) inhibitor BGB-3111 demonstrates high very good partial response (VGPR) rate in patients with Waldenström macroglobulinemia (WM). *Hematol Oncol* 2017; 35: 70–71.

103. Trotman J, Opat S, Gottlieb DJ, *et al.* Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: three years of follow-up. *Blood* 2020; 136: 2027–2037.

104. Tam CS, Opat S, D’Sa S, *et al.* A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. *Blood* 2020; 136: 2038–2050.

105. Garcia-Sanz R, Dimopoulos MA, Lee HP, *et al.* Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM). *J Clin Oncol* 2020; 38(Suppl. 15): e20056.

106. Owen RG, McCarthy H, Rule S, *et al.* Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. *Lancet Haematol* 2020; 7: e112–e121.

107. Sekiguchi N, Rai S, Munakata W, *et al.* A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom’s macroglobulinemia. *Cancer Sci* 2020; 111: 3327–3337.

108. Othman J, Verner E, Tam CS, *et al.* Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenstrom macroglobulinemia. *Haematologica* 2018; 103: e223–e225.

109. BieGene. BieGene announces results of phase 3 ASPEN trial of zanubrutinib compared to ibrutinib for the treatment of patients with
Waldenström’s macroglobulinemia. Epub ahead of print 2019. https://www.globenewswire.com/news-release/2019/12/16/1960839/0/en/BiGene-Announces-Results-of-Phase-3-ASPEN-Trial-of-Zanubrutinib-Compared-to-Ibrutinib-for-the-Treatment-of-Patients-with-Waldenstr%C3%B6m’s-Macroglobulinemia.html

110. Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. *J Pharmacol Exp Ther* 2017; 363: 240–252.

111. Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med* 2016; 374: 323–332.

112. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. *Lancet* 2018; 391: 659–667.

113. Owen R, McCarthy CA, Rule S, et al. Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM). *J Clin Oncol* 2018; 36: 7501.

114. Johnson AR, Kohli PB, Katewa A, et al. Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations. *ACS Chem Biol* 2016; 11: 2897–2907.

115. Brandhuber B, Gomez E and Smith S. Abstract CLL-200: LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors [Abstract]. *Clin Lymphoma Myeloma Leuk* 2018; 18: S216.

116. Reiff SD, Mantel R, Smith LL, et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and richter transformation. *Cancer Discov* 2018; 8: 1300–1315.

117. Soncini D, Orecchioni S, Ruberti S, et al. The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. *Haematologica* 2020; 105: 224956.

118. Bond DA and Woyach JA. Targeting BTK in CLL: beyond ibrutinib. *Curr Hematol Malig Rep* 2019; 14: 197–205.

119. Woyach J, Stephens D, Flinn I, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. *Blood* 2019; 134: 4298–4298.

120. Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, et al. The current role of BTK inhibitors in the treatment of Waldenstrom’s macroglobulinemia. *Expert Rev Anticancer Ther* 2020; 20: 663–674.